Regeneron has released late-stage safety and efficacy data on Arcalyst, making a strong regulatory filing in its quest to market the drug against gout. 

In one of its phase III studies, a pair of doses triggered a 72% mean reduction in gout flares compared to placebo, confirming the results of an earlier study. And in a separate phase III safety trial, the weekly, self-administered subcutaneous dose of rilonacept—an IL-1 Trap—was well tolerated with a higher rate of site injection reactions than the placebo arm.